Corcept Therapeutics to Share 2025 Financials and Corporate Strategy
Corcept Therapeutics Incorporated (NASDAQ: CORT) has announced it will release its fourth quarter and full-year 2025 financial results on February 24, 2026. The company will also provide a corporate update during a conference call that day, beginning at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).
Accessing the Financial Report and Conference Call
Investors and interested parties can register for the conference call in advance by clicking here. Registration will provide a unique dial-in number and access PIN for each participant. A listen-only webcast will also be available here. A replay of the call will be accessible on the Investors / Events section of the Corcept website.
Corcept’s Focus on Cortisol Modulation
For over 25 years, Corcept Therapeutics has concentrated on the role of cortisol modulation in treating serious medical conditions. The company has developed over 1,000 proprietary selective cortisol modulators and glucocorticoid receptor antagonists. Current clinical trials are focused on hypercortisolism, solid tumors, ALS, and liver disease.
Korlym® and the Treatment of Hypercortisolism
In 2012, Corcept introduced Korlym®, the first FDA-approved medication specifically for treating endogenous hypercortisolism. This marked a significant advancement in addressing this rare hormonal disorder.
Pipeline Developments and Future Outlook
Corcept is currently advancing several clinical programs, including relacorilant (Phase III for hypercortisolism and platinum-resistant ovarian tumors), dazucorilant (Phase II for ALS), and miricorilant (Phase IIb for metabolic dysfunction-associated steatohepatitis). These programs represent potential growth opportunities for the company.
Financial Snapshot (as of February 17, 2026)
According to recent data, Corcept Therapeutics has a market capitalization of approximately $4.176 billion. The stock closed at $39.63 on February 17, 2026, representing a decrease of 0.85% for the day. The company’s price-to-earnings (P/E) ratio is 45.55, with earnings per share (EPS) of $0.87.
Contact Information
Investor inquiries can be directed to [email protected]. Media inquiries should be sent to [email protected]. More information is available at www.corcept.com.
Frequently Asked Questions (FAQ)
What is hypercortisolism?
Hypercortisolism is a hormonal disorder caused by prolonged exposure to high levels of cortisol, often due to a tumor.
Where can I find more information about Corcept Therapeutics?
You can visit the company’s website at www.corcept.com.
When is Corcept Therapeutics releasing its financial results?
Corcept Therapeutics will release its fourth quarter and full-year 2025 financial results on February 24, 2026.
